Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Nabriva Therapeutics plc NBRV
$1.70
+$0.07 (3.91%)
На 18:00, 12 мая 2023
-41.18%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
5368208.00000000
-
week52high
8.45
-
week52low
1.22
-
Revenue
35668000
-
P/E TTM
-82
-
Beta
1.55363300
-
EPS
-21.25000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 ноя 2022 г. в 21:30
Описание компании
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Morgan Stanley | Equal-Weight | Equal-Weight | 07 дек 2020 г. |
| HC Wainwright & Co. | Neutral | Buy | 09 апр 2020 г. |
| H.C. Wainwright | Neutral | Buy | 09 апр 2020 г. |
| Needham | Hold | Buy | 08 апр 2020 г. |
| Wedbush | Neutral | Outperform | 19 мар 2020 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Schroeder Theodore R | D | 11989 | 431 | 29 янв 2023 г. |
| Gelone Steven P. | D | 14283 | 140 | 29 янв 2023 г. |
| Schroeder Theodore R | D | 12420 | 11 | 06 янв 2023 г. |
| Gelone Steven P. | D | 14423 | 5 | 06 янв 2023 г. |
| Gelone Steven P. | D | 14428 | 3 | 31 дек 2022 г. |
| Schroeder Theodore R | D | 12431 | 5 | 31 дек 2022 г. |
| Gelone Steven P. | D | 14431 | 4 | 06 дек 2022 г. |
| Schroeder Theodore R | D | 12436 | 9 | 06 дек 2022 г. |
| Schroeder Theodore R | D | 12445 | 5 | 30 ноя 2022 г. |
| Gelone Steven P. | D | 14435 | 3 | 30 ноя 2022 г. |
Новостная лента
7 Stocks to Sell as Banks Melt Down
InvestorPlace
20 мар 2023 г. в 18:20
Peruse the Internet for investment guidance and you're likely to hear the adage that you shouldn't consider stocks to sell when faced with volatility. Rather, you should buy up assets and securities when there's blood on the streets.
Nabriva (NBRV) Posts Positive Data From Cystic Fibrosis Study
Zacks Investment Research
29 ноя 2022 г. в 14:18
Nabriva (NBRV) posts positive top-line data from the phase I study evaluating oral and intravenous Xenleta (lefamulin) in adult patients with cystic fibrosis. Shares down.
Nabriva's stock is up after sharing antibiotic news
Market Watch
28 ноя 2022 г. в 08:20
Shares of Nabriva Therapeutics Plc NBRV, were up 13.8% in premarket trading on Monday after the company said in a news release it had positive data from a Phase 1 clinical trial assessing its antibiotic as a treatment for cystic fibrosis. The drug, Xenleta, is approved to treat community-acquired bacterial pneumonia.
Nabriva Therapeutics plc (NBRV) Q3 2022 Earnings Call Transcript
Seeking Alpha
13 ноя 2022 г. в 19:40
Nabriva Therapeutics plc (NASDAQ:NBRV ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Daniel Dolan - CFO Theodore Schroeder - CEO Conference Call Participants Carl Byrnes - Northland Capital Markets Ed Arce - H.C. Wainwright Operator Welcome to the Nabriva Therapeutics Third Quarter 2022 Financial Results Call and Corporate Update.
Nabriva Therapeutics to Report Third Quarter 2022 Financial Results and Recent Corporate Highlights on November 10, 2022
GlobeNewsWire
07 ноя 2022 г. в 07:01
DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its third quarter financial results along with recent company highlights after the close of the U.S. financial markets on Thursday, November 10, 2022. Nabriva's management will host a conference call at 4:30 p.m. ET to discuss the financial results and recent corporate highlights.